Haemophilia

Article	Citations
AHP Oral Abstracts	63
CCS_Book of abstracts	31
	31
Health‐related quality of life among adults with haemophilia in China: A comparison with age‐matched general population	29
Competence and Confidence: An Evaluation of Physiotherapists' Knowledge and Self‐Perception About Physical Activity and Exercise in Patients With Haemophilia	28
13th BIC International Conference	28
A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?	27
Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable	26
Direct transfer of data of people with haemophilia from the Thai Haemophilia Treatment Centre Registry to the World Bleeding Disorders Registry of the World Federation of Hemophilia	25
Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia	25
Into a brave new world: Haemophilia A & von Willebrand Disease Surgery with novel therapies	24
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view	24
Haemophilia B, severe childhood obesity and other extra‐haematological features associated with similar 4Mb‐deletions on Xq27: Clinical findings, molecular insights and literature update	23
The legacy of haemophilia: Memories and reflections from three survivors	22
The detrimental effects of iron to the joint; aggravation by inflammation	22
The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody	22
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	22
The importance and evolution of bleeding disorder registries	22
Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial	22
Total joint arthroplasty in the patients with haemophilia: General or neuraxial anaesthesia?	21
Is it time for patient involvement in Haemophilia?	21
Demographics, clinical profile and treatment landscape of patients with haemophilia B in China	21
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review	20
Issue Information	18
Knowledge gaps in health‐related quality of life research performed in children with bleeding disorders – A scoping review	18

Reinvestigation of unidentified causative variants in FXI‐deficient patients: Focus on gene segment deletions	18
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study	17
Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement	17
Wearable activity trackers in young people with haemophilia: What needs to be considered?	17
Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre	17
Health technology assessment for gene therapies in haemophilia	16
Profiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’	16
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	16
PUBLICATION ONLY ABSTRACTS	16
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective	16
Cost Analysis of Radioactive Versus Arthroscopic Synovectomy in Haemophilia: A Brazilian Modelling Approach	16
Initial von Willebrand factor antigen values in adolescent females predict future values	16
	16
Clinical outcomes of low‐dose pharmacokinetic‐guided extended half‐life versus low‐dose standard half‐life factor VIII concentrate prophylaxis in haemophilia A patients	15
People With Haemophilia as Data Coordinators: An Analysis of the Ethics and Feasibility of Self‐Management With Personal Health Records	15
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	15
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature	15
The UK Infected Blood Inquiry: A Personal Reflection	15
The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033	14
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy	14
AUTHOR INDEX	14
AUTHOR INDEX	14
Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency	14
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)	14
Impact of first COVID‐19 lockdown on paediatric and adult haemophilia patients treated in a French Haemophilia Comprehensive Care Centre	14
Towards achieving a haemophilia‐free mind	14
Development of the World Federation of Hemophilia Shared Decision‐Making Tool	14
Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries	14
Occurrence of familial Mediterranean fever in haemophilia patients	14
Anti‐platelet treatment challenges in Glanzmann thrombasthenia‐clinical practice when data lacks	14
P2RY12‐Related Platelet Dysfunction in an Indian Child: Unravelling the Diagnostic Enigma of Suspected Platelet Storage Pool Disorder	13
Assessment of rare bleeding disorders in adolescents with heavy menstrual bleeding	13
Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A	13
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	13
Validating the Online Self‐Administered Bleeding Assessment Tool (Self‐BAT) as a Screening Tool for Bleeding Disorders	13
Development of a target product profile (TPP) for haemophilia point‐of‐care (POC) diagnostic devices for low‐resource countries and remote settings	13
Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review	13
Factor XIII levels correlate with fibrinogen concentrations in patients with venous malformations	12
Emicizumab and asparaginase, A first experience to share	12
A 10‐year single‐institution retrospective review of treatment for acquired hemophilia A	12
Artificial Intelligence Applications in Haemophilia Care: A Narrative Review of the Literature	12
Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes	12
Factors associated with physical activity in young people with haemophilia A on prophylaxis	12
Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project	12
Clinical Course of Residual Flexion Contracture After Total Knee Arthroplasty in Patients With Haemophilic Arthropathy	12
The lived experience of mothers of children with haemophilia in Jordan: A phenomenological study	12
Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms	12
Pharmacokinetic profile of children with haemophilia A receiving low‐dose FVIII prophylaxis in Indonesia: A single centre experience	12
A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials	12
Performance on the iSTEP and 10 m‐ISWT in boys with haemophilia	11

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy	11
	11
Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A	11
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real‐Life Case Series and Literature Review	11
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients	11
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience	11
Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers	11
Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study	11
von Willebrand disease and von Willebrand factor	11
Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies	11
Book of Abstracts	11
Management of Persons With Haemophilia Requiring Antithrombotic Therapy: A Canadian Modified Delphi Consensus Study	11
F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A	11
Systematic Literature Review of Outcomes Associated With Adherence to Haemophilia Drug Therapy	11
Physical Activity Awareness and Understanding of Treatment Protection Among People With Haemophilia and Their Caregivers in Central Europe	11
	11
Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis	11
Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease	11
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity	11
The state of oral health in patients with haemophilia in the Netherlands	11
Ankle joint distraction is a promising alternative treatment for patients with severe haemophilic ankle arthropathy	10
Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients	10
Democratisation of physiotherapy for people with haemophilia	10
Scientific Review of the UK Infected Blood Inquiry Report: A Personal Reflection	10
Reduced‐Dose versus Standard‐Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study	10
Clotting Factor Concentration During Menstrual Phases in Women With and Without Heavy Menstrual Bleeding: A Systematic Review and Meta‐Analysis	10
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review	10
Retraction	10
HRQoL and psychosocial aspects of burden on caregivers to children with moderate or severe von Willebrand disease	10
Correction to “Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Hemophilia A”	10
The haemophilia joint health score for the assessment of joint health in patients with haemophilia	10
Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen	10
Commentary: The Infected Blood Inquiry in the United Kingdom—Let the Dust Settle	10
Real‐World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study	10
Dental Neglect by Individuals With Haemophilia: Clinical Challenges and Solutions	9
Patient‐centred research agenda for females with bleeding disorders	9
Does the method of telehealth delivery affect the physiotherapy management of adults with bleeding disorders? A comparison of audioconferencing and videoconferencing	9
Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal	9
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab	9
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	9
Endothelial specific isoform of type XVIII collagen (COL‐18N): A marker of vascular integrity in haemophilic arthropathy	9
Author Index	9
Immune checkpoint inhibitor‐induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system	9
Integrating Next‐Generation Sequencing Into Routine Molecular Diagnosis of Inherited Coagulation Factor Deficiencies: Real‐World Data From Spanish Patients	9
Identifying performance‐based outcome measures of physical function in people with haemophilia (IPOP)	9
The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: An integrative review	9
European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice	9
Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis	9
Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States	9
Gene therapy: Practical aspects of implementation	9
Clotting factor activity levels and bleeding risk in people with haemophilia playing sports	9
COMMITTEE LIST	8
	8
Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees	8
Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?	8
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B	8
Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency—A large single‐centre experience	8
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature	8
Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH)	8
Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐ce	8
Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State	8
UKNEQAS Blood Coagulation Factor Nine (FIX) Gene Therapy Supplementary Exercise 2025	8
Comparison of free‐living physical activity measurements between ActiGraph GT3X‐BT and Fitbit Charge 3 in young people with haemophilia	8
	8
Bone marrow oedema syndrome as a cause of chronic knee pain in a person with severe Haemophilia A	8
Hemizygous FGG p.Ala108Gly in a hypofibrinogenemic patient with a heterozygous 14.8 Mb deletion encompassing the entire fibrinogen gene cluster	8
Enhancing Engagement to Support Shared Decision Making Within Haemophilia: Development of Materials for People With Haemophilia, Caregivers and Healthcare Professionals	8
Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience	8
Five new F10 variants in hereditary factor x deficiency detected by high‐throughput sequencing	8
Validity and reliability test of the Indonesian version of the PedHALshort questionnaire	8
Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2)	7
European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients	7
Clinical, biological, and genetic features in an afibrinogenemia patient series in Algeria	7
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B	7
	7
Abstracts	7
Radiological Stage of Hemophilic Arthropathy of Knee Does Not Correlate With Clinical Variables	7
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes	7
Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study	7
Haemophilia care in Asia: Learning from clinical practice in some Asian countries	7

Treatment of haematuria with factor concentrate in people with haemophilia is associated with low rates of complications	7
POSTER PRESENTATIONS	7
Comprehensive Analysis of Surgical Interventions for Musculoskeletal Disorders in Patients With Bleeding Disorders: Report From a Subspecialty Unit in a Developing Country	7
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders	7
Psychophysical assessment of pain in adults with moderate and severe haemophilia: A cross‐sectional study	7
A systematic review and narrative synthesis of footwear and orthotic devices used in the management of ankle haemarthrosis and haemarthropathy in haemophilia	7
Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study	7
Diagnosis of rare bleeding disorders	7
Is the world ready for gene therapy?	7
Harmonizing patient‐reported outcome measurements in inherited bleeding disorders with PROMIS	7
Experiences and Needs Regarding Information Provision in Children With Haemophilia: A Qualitative Study on Caregivers’ and Healthcare Providers’ Perspectives	7
Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan	7
Committee List	7
Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences	7
Issue Information	7
Efficacy and Safety of Aspiration and Intra‐Articular Injection of Tranexamic Acid in Acute Knee Hemarthrosis of Adult Haemophilic Patients: A Randomized Clinical Trial Study	7
Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China	6
Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study	6
Morphological Variations in Haemophilic Knee Arthropathy: Surgical Implications for Total Knee Arthroplasty Component Selection and Bone Preparation	6
	6
Issue Information	6
Research Letter: Patient Attitudes Towards Haemophilia Gene Therapy at a US Haemophilia Treatment Center	6
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	6
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group	6
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	6
Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series	6
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B	6
A national assessment of standards of care for inherited bleeding disorders in Canada	6
Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database	6
	6
Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause	6
Diagnosis and treatment of von Willebrand disease in 2024 and beyond	6
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy	6
Prevalence and Impact of Heavy Menstrual Bleeding in Women With von Willebrand Disease Across Age Groups: A Retrospective Study	6
Coagulation Factor Consumption and Medium‐ to Long‐Term Outcomes of Achilles Tendon Lengthening With and Without External Fixation in Haemophilia	6
Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience	6
POSTER ABSTRACTS	6
Haemophilic Elbow Arthropathy: Mechanisms, Management and Future Perspectives	6
Deciphering a novel complex inversion affecting F8 in a family with severe haemophilia A by optical genome mapping	6
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy	6
Identification and Analysis of Mitochondria‐Related Proteins in Haemophilic Arthritis Synovial Membranes Based on Proteomic Analysis	6
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry	6
UK haemophilia consultant access to foot and ankle services and concurrent patient impact questionnaire responses to foot and ankle interventions	6
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot®) and emicizumab in patients with haemophilia A and inhibitors and	6
Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding	6
Supporting Patient‐Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model	5
Cross‐Sectional Survey of Haemophilia Treatment Centres (HTCs) in India: Towards a Context‑Sensitive Stratification Model	5
Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States	5
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A	5
Haemostatic Prophylaxis and Colonoscopy Outcomes in Patients With Bleeding Disorders: An Update	5
Germline variants of the immune checkpoint proteins PD‐1, PD‐l1 and CTLA‐4 and immune tolerance induction outcome in patients with inherited haemophilia A	5
Severe haemorrhages leading to a diagnosis of rare bleeding disorder occur at a very young age: A study from the FranceCoag network	5
Real‐world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea	5
Women and girls’ participation in haemophilia clinical trials	5
Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group	5
Molecular spectrum of inherited FVII deficiency in North India revealed a recurrent variant with a founder effect	5
Desmopressin Response in Children With Platelet Disorders May Depend on the Presence of a Genetic Cause When Response Is Measured With Von Willebrand Activity and Platelet Function Analyser	5
Defining success in haemophilia care – Are we doing it right?	5
ImpaHCta—Haemophilia Carriers Quality of Life Assessment	5
The effect of a virtual child disease management programme on burden and social adjustment of caregivers of children with coagulation factor deficiencies	5
Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab	5
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 1	5
Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B	5
AUTHOR INDEX	5
Mobilization under anaesthesia for correction of knee flexion deformity in haemophilia	5
Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment	5
Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe	5
Depression and anxiety in persons with Von Willebrand disease	5
	5
Differences and similarities in patient‐reported outcomes among men and women with haemophilia	5
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD	5
	5
The effect of carriers’ reproductive choices and pregnancy history on sporadic severe haemophilia: A 20‐year retrospective study through a regional registry	5
Acquired bleeding disorders	5
Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis	5
Issue Information	5
Association of factor expression levels with annual bleeding rate in people with haemophilia B	5
Psychological and cognitive factors involved in decision‐making process of haemophilia carriers in reproductive choices	5
EAHAD statement on the ISTH clinical practice guideline for treatment of congenital haemophilia A and B	5
Invited Medical Presentation Abstracts	5
Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey	4
The 2021 von Willebrand disease guidelines: Clarity and controversy	4
Iron deficiency anemia and bleeding management in pediatric patients with Bernard‐Soulier syndrome and Glanzmann Thrombasthenia: A single‐institution analysis	4
Review of interventions and effectiveness for heavy menstrual bleeding in women with moderate and severe von Willebrand disease	4
Assay of Efanesoctocog Alfa in 200 Centres: Data from Collaborative NEQAS BC (United Kingdom) and ECAT (Netherlands) Exercise Autumn 2024	4
Treatment and Disease Burden in a Cohort of People With Haemophilia Without Inhibitors in the United States	4
Haemophilia‐Related Pain: A Bibliometric and Content Analysis of Research Trends and Key Themes	4
Longitudinal observations of TFPI levels in paediatric Haemophilia A patients	4
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐se	4
Outcomes and outcome measures	4
	4
Iron overload causes macrophages to produce a pro‐inflammatory phenotype in the synovium of hemophiliac arthritis via the acetyl‐p53 pathway	4
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro	4
Issue Information	4
Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single‐institution cohort study	4